Last reviewed · How we verify
TDT067 and Lamisil — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
TDT067 and Lamisil (TDT067 and Lamisil) — Celtic Pharma Development Services.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| TDT067 and Lamisil TARGET | TDT067 and Lamisil | Celtic Pharma Development Services | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- TDT067 and Lamisil CI watch — RSS
- TDT067 and Lamisil CI watch — Atom
- TDT067 and Lamisil CI watch — JSON
- TDT067 and Lamisil alone — RSS
Cite this brief
Drug Landscape (2026). TDT067 and Lamisil — Competitive Intelligence Brief. https://druglandscape.com/ci/tdt067-and-lamisil. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab